Liquid Biopsy in Malignant Pleural Mesothelioma: State of the Art, Pitfalls, and Perspectives

Ilaria Cavallari, Loredana Urso, Evgeniya Sharova, Giulia Pasello, Vincenzo Ciminale

Research output: Contribution to journalReview article

Abstract

Malignant pleural mesothelioma (MPM) is an aggressive tumor linked to asbestos exposure. Although the risk factors for MPM are well-known, the majority of MPM patients are diagnosed at an advanced stage and have a very poor prognosis. Circulating biomarkers for early diagnosis remain to be identified, and the current standard for MPM diagnosis relies on pleural biopsies. Robust non-invasive tests for the screening of asbestos-exposed subjects are therefore an important unmet clinical need. This review provides a critical summary of recent liquid biopsy-based studies aimed at discovering novel blood-based circulating biomarkers for the early diagnosis and prognostic stratification of MPM patients.

Original languageEnglish
Article number740
Pages (from-to)1-13
Number of pages13
JournalFrontiers in Oncology
Volume9
DOIs
Publication statusPublished - 2019

Fingerprint Dive into the research topics of 'Liquid Biopsy in Malignant Pleural Mesothelioma: State of the Art, Pitfalls, and Perspectives'. Together they form a unique fingerprint.

  • Cite this